Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany

详细信息    查看全文

• 作者：Bernhard Ultsch (18) (19)
  Felix Weidemann (18)
  Thomas Reinhold (20)
  Anette Siedler (18)
  Gérard Krause (21) (22)
  Ole Wichmann (18)
  
• 关键词：Herpes zoster ; Postherpetic neuralgia ; Vaccine ; Cost ; effectiveness ; QALY ; Markov
• 刊名：BMC Health Services Research
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：13
• 期：1
• 全文大小：649 KB
• 参考文献：1. Klein S, Sch?neberg I, Krause G: Vom Zwang zur Pockenschutzimpfung zum Nationalen Impfplan. / Bundesgesundheitsbl 2012,55(11-2):1512-523. CrossRef
  2. Wutzler P, F?rber I, Wagenpfeil S, Bisanz H, Tischer A: Seroprevalence of varicella-zoster virus in the German population. / Vaccine 2001,20(1-):121-24. CrossRef
  3. Breuer J, Whitley R: Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. / Herpes 2007,14(Suppl 2):25-9.
  4. Hope-Simpson RE: The nature of Herpes Zoster: a long-term study and a new hypothesis. / Proc R Soc Med 1965, 58:9-0.
  5. Wittek M, Doerr HW, Allwinn R: Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. / Med Klin (Munich) 2010,105(5):334-38. CrossRef
  6. Schmader K, Gnann JW Jr, Watson CP: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. / J Infect Dis 2008,197(Suppl 2):S207-S215. CrossRef
  7. Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, Camden S, Mansi JA: A prospective study of the herpes zoster severity of illness. / Clin J Pain 2010,26(8):656-66.
  8. Opstelten W, Eekhof J, Neven AK, Verheij T: Treatment of herpes zoster. / Can Fam Physician 2008,54(3):373-77.
  9. Forbes H, Thomas S, Langan S: The Epidemiology and Prevention of Herpes Zoster. / Curr Dermat Rep 2012,1(1):39-7. CrossRef
  10. Hope-Simpson RE: Postherpetic neuralgia. / J R Coll Gen Pract 1975,25(157):571-75.
  11. Jericho BG: Postherpetic neuralgia: a review. / Internet Journal of Pain, Symptom Control and Palliative Care 2010.,8(1):
  12. Dworkin RH, Portenoy RK: Pain and its persistence in herpes zoster. / Pain 1996,67(2-):241-51. CrossRef
  13. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD: Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. / J Pain 2005,6(6):356-63. CrossRef
  14. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA: The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. / CMAJ 2010,182(16):1731-736. CrossRef
  15. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, / et al.: The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. / Clin J Pain 2007,23(6):490-96. CrossRef
  16. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH: Acute pain in herpes zoster and its impact on health-related quality of life. / Clin Infect Dis 2004,39(3):342-48. CrossRef
  17. Edmunds WJ, Brisson M, Rose JD: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. / Vaccine 2001,19(23-4):3076-090. CrossRef
  18. Miller E, Marshall R, Vurdien J: Epidemiology, outcome and control of varicella-zoster infection. / Rev Med Microbiol 1993,4(4):222-30. CrossRef
  19. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G: Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. / Epidemiol Infect 2001,127(2):305-14. CrossRef
  20. Donahue JG, Choo PW, Manson JE, Platt R: The incidence of herpes zoster. / Arch Intern Med 1995,155(15):1605-609. CrossRef
  21. Ultsch B, K?ster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O: Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. / Eur J Health Econ 2012, 1-2.
  22. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O: Herpes zoster in Germany: quantifying the burden of disease. / BMC Infect Dis 2011,11(1):173. CrossRef
  23. Schiffner-Rohe J, Jow S, Lilie HM, K?ster I, Schubert I: Herpes zoster in Deutschland - Eine retrospektive Analyse von GKV-Daten. / MMW Fortschr Med Originalien 2009, 151:193-97.
  24. Volpi A, Gross G, Hercogova J, Johnson RW: Current management of herpes zoster: the European view. / Am J Clin Dermatol 2005,6(5):317-25. CrossRef
  25. Johnson RW, Wasner G, Saddier P, Baron R: Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. / Drugs Aging 2008,25(12):991-006. CrossRef
  26. Alper BS, Lewis PR: Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? / J Fam Pract 2000,49(3):255-64.
  27. Wittek M, Doerr HW, Allwinn R: Varicella and herpes zoster. Part 2: therapy and prevention. / Med Klin (Munich) 2010,105(6):399-03. CrossRef
  28. Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW: Herpes zoster guideline of the German Dermatology Society (DDG). / J Clin Virol 2003,26(3):277-89. discussion 291-73 CrossRef
  29. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, / et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. / N Engl J Med 2005,352(22):2271-284. CrossRef
  30. Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su S-C: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-9 years. / Clin Infect Dis 2012,54(7):922-28. CrossRef
  31. / Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [ClinicalTrials.gov Identifier NCT01165177] last update February 7, 2013. 2013. http://clinicaltrials.gov/ct2/show/NCT01165177?term=herpes+zoster&spons=GlaxosmithKline&age=12&phase=2&rank=1
  32. Drummond M, Chevat C, Lothgren M: Do we fully understand the economic value of vaccines? / Vaccine 2007,25(32):5945-957. CrossRef
  33. / Gesetzliche Krankenversicherung Mitglieder,mitversicherte Angeh?rige und Krankenstand Monatswerte Januar-Mai 2013. 2013. http://bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/Statistiken/GKV/Mitglieder_Versicherte/KM1_Januar_Mai_2013.pdf
  34. Annemans L, Bresse X, Gobbo C, Papageorgiou M: Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. / J Med Econ 2010,13(3):537-51. CrossRef
  35. Brisson M: Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. / Can J Public Health 2008,99(5):383-86.
  36. Gauthier A, Breuer J, Carrington D, Martin M, Remy V: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. / Epidemiol Infect 2009,137(1):38-7. CrossRef
  37. Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow O, Blanchon T, Hanslik T: Herpes zoster: burden of disease in France. / Vaccine 2010,28(50):7933-938. CrossRef
  38. Max M, Schafer S, Culnane M, Smoller B, Dubner R, Gracely R: Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. / Neurology 1988,38(9):1427. CrossRef
  39. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA: Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. / Fam Pract 2002,19(5):471-75. CrossRef
  40. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ: Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. / Vaccine 2009,27(9):1454-467. CrossRef
  41. Yawn BP: Post-shingles neuralgia by any definition is painful, but is it PHN? / Mayo Clin Proc 2011,86(12):1141-142. CrossRef
  42. / General Methods for Assessment of the Relation of Benefits to Costs. https://www.iqwig.de/download/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Cost.pdf
  43. / Cost estimation - working paper, Version 1.0. https://www.iqwig.de/download/Working_Paper_Cost_Estimation.pdf
  44. Gnann JW Jr, Whitley RJ: Clinical practice. Herpes zoster. / N Engl J Med 2002,347(5):340-46. CrossRef
  45. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO: Population-based study of herpes zoster and its sequelae. / Medicine (Baltimore) 1982,61(5):310-16.
  46. Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ: Herpes zoster Vaccine and the incidence of Recurrent Herpes Zoster in an immunocompetent elderly population. / J Infect Dis 2012,55(10):1320-328.
  47. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P: Herpes zoster recurrences more frequent than previously reported. / Mayo Clin Proc 2011,86(2):88-3. CrossRef
  48. / Bev?lkerung und Erwerbst?tigkeit - Sterbetafel Deutschland. https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefaelle/Tabellen/SterbetafelDeutschland.xls?__blob=publicationFile
  49. Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG: Vaccines for preventing herpes zoster in older adults. / Cochrane Database Syst Rev 2012, 10:CD008858.
  50. Oxman MN, Levin MJ: Vaccination against Herpes Zoster and Postherpetic Neuralgia. / J Infect Dis 2008,197(Suppl 2):S228-S236. CrossRef
  51. FDA: FDA Clinical Briefing Document for Merck & Co., Inc. Zoster vaccine live (Oka/Merck) Zostavax? In / Vaccines and Related Biological Products Advisory Committee Edited by: US-Food-and-Drug-Administration. 2005.
  52. Schmader K, Oxman M, Levin M, Betts R, Morrison V, Gelb L, Johnson G, Zhang J, Li X, Annunziato P: Persistence of Zoster Vaccine Efficacy. / ICAAC/IDSA: 2008; Durham 2008.
  53. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, / et al.: Persistence of the Efficacy of Zoster Vaccine in the Shingles prevention study and the short-term persistence substudy. / Clin Infect Dis 2012.
  54. Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P: Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. / Vaccine 2012,30(3):675-84. CrossRef
  55. Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P: Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? / Vaccine 2012,30(17):2795-800. CrossRef
  56. Pellissier JM, Brisson M, Levin MJ: Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. / Vaccine 2007,25(49):8326-337. CrossRef
  57. MMWR: / Noninfluenza Vaccination Coverage Among Adults -United States. 2011. http://www.cdc.gov/mmwr/pdf/wk/mm62e0129.pdf
  58. / Epidemiologisches Bulletin. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2002/Ausgabenlinks/16_02.pdf?__blob=publicationFile
  59. / Lauer-Taxe online - Preisinfo: ZOSTAVAX. 2010. http://www2.lauer-fischer.de/home/
  60. Briggs A, Claxton K, Sculpher M: / Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2008.
  61. Hinz A, Klaiberg A, Brahler E, Konig HH: [The quality of life questionnaire EQ-5D: modelling and norm values for the general population]. / Psychother Psychosom Med Psychol 2006,56(2):42-8. CrossRef
  62. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T: Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. / Health Econ 2005,14(4):339-47. CrossRef
  63. Welte R, Feenstra T, Jager H, Leidl R: A decision chart for assessing and improving the transferability of economic evaluation results between countries. / Pharmacoeconomics 2004,22(13):857-76. CrossRef
  64. Jacobzone S: Pharmaceutical Policies in OECD Countries. In / Reconciling Social and Industrial Goals. Edited by: 40 OLMaSPOPN. Paris: OECD; 2000. CrossRef
  65. Mick G, Hans G: Postherpetic neuralgia in Europe: The scale of the problem and outlook for the future. / J Clin Gerontol Geriatr 2013.
  66. Reda H, Greene K, Rice FL, Rowbotham MC, Petersen KL: Natural History of Herpes Zoster: Late follow-up 3.9 yrs (n= 43) and 7.7 yrs (n= 10). / PAIN 2013, 10:2227-233. CrossRef
  67. van Lier A, van Hoek AJ, Opstelten W, Boot H, de Melker H: Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. / BMC Health Serv Res 2010,10(1):237. CrossRef
  68. De Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ: Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. / Vaccine 2013,31(9):1276-283. CrossRef
  69. Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X: Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. / Hum Vaccin 2011,7(7):749-56. CrossRef
  70. Bresse X, Annemans L, Preaud E, Bloch K, Duru G, Gauthier A: Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. / Expert Rev Pharmacoecon Outcomes Res 2013,13(3):393-06. CrossRef
  71. Moore L, Remy V, Martin M, Beillat M, McGuire A: A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. / Cost Effectiveness and Resource Allocation 2010,8(1):7. CrossRef
  72. Hornberger J, Robertus K: Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. / Ann Intern Med 2006,145(5):317-25. CrossRef
  73. Rothberg MB, Virapongse A, Smith KJ: Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. / Clin Infect Dis 2007,44(10):1280-288. CrossRef
  74. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P: The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. / Hum Vaccin 2008,4(3):238-45. CrossRef
  75. Najafzadeh M, Marra CA, Galanis E, Patrick DM: Cost effectiveness of herpes zoster vaccine in Canada. / Pharmacoeconomics 2009,27(12):991-004. CrossRef
  76. Szucs TD, Pfeil AM: A systematic review of the cost effectiveness of herpes zoster vaccination. / Pharmacoeconomics 2013,31(2):125-36. CrossRef
  77. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, / et al.: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. / J Pain 2004,5(6):344-56. CrossRef
  78. Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B: Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. / Journal of clinical epidemiology 1998,51(8):667-76. CrossRef
  79. Graf Von Der Schulenburg JM, Claes C, Greiner W, / et al.: Die deutsche Version des EuroQol-Fragebogens. / Zeitschrift für Gesundheitswissenschaften 1998, 6:3-0.
  80. Hoebel J, Kuntz B, Muters S, Lampert T: Subjective Social Status and Health-Related Quality of Life among Adults in Germany. / Gesundheitswesen 2013.
  81. Konig HH, Bernert S, Angermeyer MC: Health status of the German population: results of a representative survey using the EuroQol questionnaire. / Gesundheitswesen 2005,67(3):173-82. CrossRef
  82. Mielck A, Vogelmann M, Schweikert B, Leidl R: Health status of adults in Germany: results from a representative survey using the EuroQol 5D (EQ-5D). / Gesundheitswesen 2010,72(8-):476-86. CrossRef
  83. Pierik J, Gumbs P, Fortanier S, Van Steenwijk P, Postma M: Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. / BMC Infect Dis 2012,12(1):110. CrossRef
  84. Gialloreti L, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo R, Volpi A: Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. / BMC Infect Dis 2010,10(1):230. CrossRef
  85. Cebrian-Cuenca A, Diez-Domingo J, San-Martin-Rodriguez M, Puig-Barbera J, Navarro-Perez J: Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. / BMC Infect Dis 2011,11(1):302. CrossRef
  86. Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A: Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax ^? ) in individuals aged ?70 years: a randomized study of a single dose vs. two different two-dose schedules. / Human Vaccines & Immunotherapeutics 2013,9(4):854-60. CrossRef
  87. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/13/359/prepub
  
• 作者单位：Bernhard Ultsch (18) (19)
  Felix Weidemann (18)
  Thomas Reinhold (20)
  Anette Siedler (18)
  Gérard Krause (21) (22)
  Ole Wichmann (18)
  
  18. Immunisation Unit, Robert Koch Institute, Berlin, Germany
  19. Charité University Medical Centre, Berlin, Germany
  20. Institute for Social Medicine, Epidemiology and Health Economics, Charité - University Medical Centre, Berlin, Germany
  21. Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
  22. Department for Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Germany
  
• ISSN：1472-6963

文摘

Background Herpes zoster (HZ) is a self-limiting painful skin rash affecting mostly individuals from 50 years of age. The main complication is postherpetic neuralgia (PHN), a long-lasting pain after rash has resolved. A HZ-vaccine has recently been licensed in Europe for individuals older than 50 years. To support an informed decision-making for a potential vaccination recommendation, we conducted a health economic evaluation to identify the most cost-effective vaccination strategy. Methods We developed a static Markov-cohort model, which compared a vaccine-scenario with no vaccination. The cohort entering the model was 50 years of age, vaccinated at age 60, and stayed over life-time in the model. Transition probabilities were based on HZ/PHN-epidemiology and demographic data from Germany, as well as vaccine efficacy (VE) data from clinical trials. Costs for vaccination and HZ/PHN-treatment (in Euros; 2010), as well as outcomes were discounted equally with 3% p.a. We accounted results from both, payer and societal perspective. We calculated benefit-cost-ratio (BCR), number-needed-to-vaccinate (NNV), and incremental cost-effectiveness ratios (ICERs) for costs per HZ-case avoided, per PHN-case avoided, and per quality-adjusted life-year (QALY) gained. Different target age-groups were compared to identify the most cost-effective vaccination strategy. Base-case-analysis as well as structural, descriptive-, and probabilistic-sensitivity-analyses (DSA, PSA) were performed. Results When vaccinating 20% of a cohort of 1 million 50 year old individuals at the age of 60 years, approximately 20,000 HZ-cases will be avoided over life-time. The NNV to avoid one HZ (PHN)-case was 10 (144). However, with a BCR of 0.34 this vaccination-strategy did not save costs. The base-case-analysis yielded an ICER of 1,419 (20,809) Euros per avoided HZ (PHN)-case and 28,146 Euros per QALY gained. Vaccination at the age of 60 was identified in most (sensitivity) analyses to be the most cost-effective vaccination strategy. In DSA, vaccine price and VE were shown to be the most critical input-data. Conclusions According to our evaluation, HZ-vaccination is expected to avoid HZ/PHN-cases and gain QALYs to higher costs. However, the vaccine price had the highest impact on the ICERs. Among different scenarios, targeting individuals aged 60 years seems to represent the most cost-effective vaccination-strategy.